New treatment approach for non-small cell lung cancer using nano-immunotherapy
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
['FUNDING_SBIR_2'] · PDX PHARMACEUTICALS, INC. · NIH-10792640
This study is testing a new treatment called ARAC that uses tiny particles to help boost the power of current therapies for non-small cell lung cancer, aiming to make them work better and improve survival for patients.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PDX PHARMACEUTICALS, INC. (nih funded) |
| Locations | 1 site (Portland, UNITED STATES) |
| Trial ID | NIH-10792640 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel nano-immunotherapy called ARAC, which aims to enhance the effectiveness of existing immune checkpoint inhibitors for treating non-small cell lung cancer (NSCLC). The approach involves creating nanoparticles that can deliver multiple therapeutic agents directly to cancer cells, improving the chances of a curative outcome. By combining a targeted cancer therapy, an immune checkpoint inhibitor, and an immune stimulant, this treatment seeks to overcome the limitations of current therapies and improve patient survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded adequately to existing treatments.
Not a fit: Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes and survival rates for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in using nanoparticle-based therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Portland, UNITED STATES
- PDX PHARMACEUTICALS, INC. — Portland, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NGAMCHERDTRAKUL, WORAPOL — PDX PHARMACEUTICALS, INC.
- Study coordinator: NGAMCHERDTRAKUL, WORAPOL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, Cancers